Loading organizations...
§ Private Profile · New York City, NY, USA
OOVA is a technology company.
Oova provides an at-home hormone monitoring system designed for women’s health, specifically tracking fertility and perimenopause. The company’s core offering is a clinical-grade test kit that measures daily, lab-accurate levels of luteinizing hormone (LH), estrogen, and progesterone. This data integrates with an AI-powered application, delivering personalized insights and a comprehensive view of hormonal patterns to users within minutes.
The company was founded by Dr. Amy Divaraniya, who serves as CEO. With a PhD in Biomedical Sciences and over a decade of experience in data science, Dr. Divaraniya identified a critical need for accessible and precise hormone data to demystify women’s reproductive health. Her insight led to the development of a solution that translates complex biological signals into actionable information.
Oova primarily serves women seeking to understand their hormonal cycles, particularly those tracking fertility or managing perimenopausal changes. The company's vision is to fully illuminate a woman's fertility journey, empowering both individuals and their healthcare providers with clear data-driven steps. It aims to offer comprehensive support in navigating significant life stages through advanced biomarker analysis.
OOVA has raised $11.0M across 2 funding rounds.
OOVA has raised $11.0M in total across 2 funding rounds.
OOVA is a biomarker health technology company specializing in at-home urine testing for hormone monitoring, initially focused on fertility and expanding into perimenopause, women's health, men's health, infant health, and chronic disease.[1][2][3][5] It builds an AI-powered platform that measures key hormones like luteinizing hormone (LH), progesterone metabolite (PdG), and estrogen metabolite (E3G) with 99% lab-grade accuracy via daily urine strips scanned by a mobile app, serving women seeking fertility insights, perimenopause validation, and clinicians needing real-time data.[4][5] OOVA solves the problem of inaccessible, personalized reproductive health data—especially for the 86% of women without a standard 28-day cycle—by providing quantitative hormone profiles that detect ovulation, fertility windows, PCOS risks, and perimenopause symptoms without blood draws, enabling at-home tracking and HIPAA-compliant provider reports.[1][3][4][5] Growth momentum includes partnerships like Thorne Research, backing from investors such as BBG Ventures and The Helm, trust from 100+ clinics and 400+ providers, a 4.9-star rating, and clinical validation by ASRM, ACOG, and The Menopause Society, with a reported +46% increase in successful pregnancies for fertility patients.[2][5]
OOVA spun out from Mount Sinai Hospital in New York City in 2019 as a fertility diagnostic company, founded by Co-Founder and CEO Aparna (Amy) Divaraniya, PhD (a biomedical engineer), Co-Founder and CTO Jerome Scelza, and a doctor—all of whom faced personal fertility challenges.[1][4] The idea emerged from innovative biochemistry and AI developed at Mount Sinai's Institute for Next Generation Healthcare, involving OB/GYNs, reproductive endocrinologists, and fertility specialists from the start to ensure clinically actionable insights.[1][4] Early traction came from three years of R&D using real human urine samples (no synthetics), a partnership with Thorne Research for direct-to-consumer fertility mapping, and clinician involvement that achieved 75% clinic conversion rates by proving data legitimacy over branding.[1][2][4]
OOVA rides the wave of personalized women's health tech and at-home diagnostics, addressing decades of research neglect where most fertility tools assume a "normal" 28-day cycle, leaving 86% of women underserved.[3] Timing aligns with rising demand for remote monitoring post-COVID, AI-driven precision medicine, and perimenopause awareness amid aging populations. Market forces like clinician data gaps, HIPAA-compliant telehealth integration, and expansion into men's/infant/chronic disease via 55+ biomarkers position it to disrupt $50B+ fertility and hormone testing markets.[2][5] It influences the ecosystem by setting standards for quantitative at-home hormone data, bridging consumers and providers, and enabling outcomes like higher pregnancy rates while scaling to broader biomarker health.[1][2][5]
OOVA is poised to evolve from a fertility leader into a multi-biomarker diagnostics platform, with near-term launches in perimenopause (already live), men's health, infant health, and chronic disease within 1-5 years.[2][5] Trends like AI personalization, telehealth growth, and women's health investment (e.g., clinician-validated data) will accelerate adoption, potentially capturing shares in expanding at-home testing amid regulatory nods from medical societies.[5] Its influence may grow by powering provider workflows and consumer empowerment, solidifying OOVA as the go-to for demystifying bodies through trusted, scalable data—echoing its mission to make women's health no longer a black box.[1]
OOVA has raised $11.0M across 2 funding rounds. Most recently, it raised $10.0M Series A in June 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2023 | $10M Series A | Sara Eshelman | BIG Idea Ventures, Byld Ventures, Hannah Bronfman, Sara Blakely, Connecticut Innovations, Jefferson Health, Eduardo Hariton, Virgin Group | Announced |
| Jun 1, 2021 | $1M Seed | BBG Ventures, Special Situations Life Sciences Fund | Next Play Ventures, Company Ventures | Announced |
OOVA has raised $11.0M in total across 2 funding rounds.
OOVA's investors include Sara Eshelman, Big Idea Ventures, Byld Ventures, Hannah Bronfman, Sara Blakely, Connecticut Innovations, Jefferson Health, Eduardo Hariton, Virgin Group, BBG Ventures, Special Situations Life Sciences Fund, Next Play Ventures.